News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Subscribe To Our Newsletter & Stay Updated
